Size | Price | Stock | Qty |
---|---|---|---|
250mg |
|
||
500mg |
|
||
Other Sizes |
|
ln Vitro |
Although 3,3'-Diindolylmethane (DIM) has less visible structural similarity to the endogenous AR ligand dihydrotestosterone (DHT), it is a powerful antagonist of androgen-acquisition receptor (AR) function. The primary byproduct of indole-3-carbinol digestion, which is a potentially anticancer ingredient in cruciferous products, is 3,3'-Diindolemethane. In L., 3,3'-Diindolylmethane demonstrates strong anticancer activity as well as antiandrogenic qualities. LNCaP cell proliferation is regulated by 3,3'-diindolylmethane, which also prevents DHT from stimulating DNA synthesis. Moreover, 3,3'-diindolylmethane suppresses DHT-induced stimulation in LNCaP cells and controls the equilibrium of endogenous PSA. Furthermore, the Pioneer promoter of the DHT victim controlled the expression of the reporter construct in suspension-transfected LNCaP cells by adjusting the 3,3′-diindolylmethane concentration. Co-administration of 50 μM 3,3'-diindolylmethane showed where AR was located in the cytoplasm and nucleus and partially prevented AR translocation brought on by DHT administration. Moreover, treatment with 3,3′-diindolylmethane inhibited the nucleus's ability to create AR foci. The sole source of fluorescein, which is mostly found in the cytoplasm, is 3,3'-diindolylmethane [1].
|
---|---|
ln Vivo |
For 30 days, subjects were split into two groups at random and given subcutaneous injections of either vehicle or 3,3'-diindolylmethane (10 mg/kg). Every three days, the subjects' body weight and tumor volume were measured with calipers. Treatment with 3,3'-Diindolylmethane (DIM) markedly slowed the growth of SNU-484 xenograft tumors. Interestingly, the turning body weight 30 days post-drug irradiation did not differ appreciably from the vehicle simulator's, suggesting that 3,3'-diindolylmethane is not highly harmful to mice. When combined, our results show that 3,3'-diindolylmethane strongly suppresses SNU-484 xenografts' ability to develop in vivo through YAP inactivation [2].
|
References |
|
Additional Infomation |
3,3'-diindolylmethane is a member of indoles. It has a role as an antineoplastic agent and a P450 inhibitor.
Diindolylmethane has been used in trials studying the prevention and treatment of SLE, Prostate Cancer, Cervical Dysplasia, Stage I Prostate Cancer, and Stage II Prostate Cancer, among others. 3,3'-Diindolylmethane has been reported in Brassica oleracea, Arundina graminifolia, and other organisms with data available. Diindolylmethane is a phytonutrient and plant indole found in cruciferous vegetables including broccoli, Brussels sprouts, cabbage, cauliflower and kale, with potential anti-androgenic and antineoplastic activities. As a dimer of indole-3-carbinol, diindolylmethane (DIM) promotes beneficial estrogen metabolism in both sexes by reducing the levels of 16-hydroxy estrogen metabolites and increasing the formation of 2-hydroxy estrogen metabolites, resulting in increased antioxidant activity. Although this agent induces apoptosis in tumor cells in vitro, the exact mechanism by which DIM exhibits its antineoplastic activity in vivo is unknown. |
Molecular Formula |
C17H14N2
|
---|---|
Molecular Weight |
246.30646
|
Exact Mass |
246.115
|
CAS # |
1968-05-4
|
PubChem CID |
3071
|
Appearance |
Off-white to pink solid powder
|
Density |
1.3±0.1 g/cm3
|
Boiling Point |
504.8±30.0 °C at 760 mmHg
|
Melting Point |
167 °C
|
Flash Point |
232.5±15.8 °C
|
Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
Index of Refraction |
1.765
|
LogP |
4.05
|
Hydrogen Bond Donor Count |
2
|
Hydrogen Bond Acceptor Count |
0
|
Rotatable Bond Count |
2
|
Heavy Atom Count |
19
|
Complexity |
286
|
Defined Atom Stereocenter Count |
0
|
SMILES |
C1(CC2=CNC3=C2C=CC=C3)=CNC4=C1C=CC=C4
|
InChi Key |
VFTRKSBEFQDZKX-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C17H14N2/c1-3-7-16-14(5-1)12(10-18-16)9-13-11-19-17-8-4-2-6-15(13)17/h1-8,10-11,18-19H,9H2
|
Chemical Name |
3-(1H-indol-3-ylmethyl)-1H-indole
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~405.99 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (10.15 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.0599 mL | 20.2996 mL | 40.5992 mL | |
5 mM | 0.8120 mL | 4.0599 mL | 8.1198 mL | |
10 mM | 0.4060 mL | 2.0300 mL | 4.0599 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01846364 | TERMINATED | Dietary Supplement: Diindolylmethane (DIM) | Proliferative Thyroid Disease | The New York Eye & Ear Infirmary | 2006-11 | Early Phase 1 |
NCT00392652 | COMPLETED | Drug: oral microencapsulated diindolylmethane | Healthy, no Evidence of Disease | National Cancer Institute (NCI) | 2006-11 | Phase 1 |
NCT00212381 | COMPLETED | Drug: di indolylmethane (DIM) Dietary Supplement: Red rice bran |
Cervical Dysplasia | New York Presbyterian Hospital | 2000-09 | Phase 3 |
NCT02525159 | COMPLETED | Dietary Supplement: DIM pills Other: Placebo Pill |
Breast Cancer | Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes | 2006-08 | Phase 3 |
NCT01022333 | UNKNOWN STATUS | Dietary Supplement: Diindolylmethane (DIM) | Breast Cancer | Women's College Hospital | 2009-07 | Phase 1 |